nodes	percent_of_prediction	percent_of_DWPC	metapath
Doxylamine—HRH1—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0436	0.0555	CbGpPWpGaD
Doxylamine—CHRM1—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0434	0.0553	CbGpPWpGaD
Doxylamine—HRH1—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.0372	0.0473	CbGpPWpGaD
Doxylamine—CHRM1—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.037	0.0472	CbGpPWpGaD
Doxylamine—HRH1—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.0361	0.046	CbGpPWpGaD
Doxylamine—CHRM1—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.036	0.0458	CbGpPWpGaD
Doxylamine—HRH1—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.0336	0.0428	CbGpPWpGaD
Doxylamine—CHRM1—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.0335	0.0427	CbGpPWpGaD
Doxylamine—HRH1—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.0312	0.0398	CbGpPWpGaD
Doxylamine—CHRM1—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.0311	0.0397	CbGpPWpGaD
Doxylamine—HRH1—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.0303	0.0386	CbGpPWpGaD
Doxylamine—CHRM1—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.0302	0.0385	CbGpPWpGaD
Doxylamine—HRH1—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.0283	0.036	CbGpPWpGaD
Doxylamine—CHRM1—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.0282	0.0359	CbGpPWpGaD
Doxylamine—Chlorphenamine—SLC6A3—Gilles de la Tourette syndrome	0.0245	0.114	CrCbGaD
Doxylamine—HRH1—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.0235	0.03	CbGpPWpGaD
Doxylamine—CHRM1—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.0235	0.0299	CbGpPWpGaD
Doxylamine—Benzphetamine—SLC6A3—Gilles de la Tourette syndrome	0.0208	0.0966	CrCbGaD
Doxylamine—Atomoxetine—SLC6A3—Gilles de la Tourette syndrome	0.0206	0.0958	CrCbGaD
Doxylamine—Cyclobenzaprine—HTR2A—Gilles de la Tourette syndrome	0.0201	0.0937	CrCbGaD
Doxylamine—HRH1—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.0198	0.0252	CbGpPWpGaD
Doxylamine—CHRM1—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.0197	0.0251	CbGpPWpGaD
Doxylamine—Promazine—DRD4—Gilles de la Tourette syndrome	0.0179	0.0832	CrCbGaD
Doxylamine—Amitriptyline—DRD3—Gilles de la Tourette syndrome	0.0134	0.0624	CrCbGaD
Doxylamine—Imipramine—SLC6A3—Gilles de la Tourette syndrome	0.0126	0.0585	CrCbGaD
Doxylamine—Doxepin—DRD2—Gilles de la Tourette syndrome	0.012	0.0559	CrCbGaD
Doxylamine—Atomoxetine—HTR2A—Gilles de la Tourette syndrome	0.0118	0.0551	CrCbGaD
Doxylamine—Promazine—DRD2—Gilles de la Tourette syndrome	0.0107	0.0496	CrCbGaD
Doxylamine—Imipramine—DRD2—Gilles de la Tourette syndrome	0.00935	0.0435	CrCbGaD
Doxylamine—Amitriptyline—DRD2—Gilles de la Tourette syndrome	0.00929	0.0432	CrCbGaD
Doxylamine—Doxepin—HTR2A—Gilles de la Tourette syndrome	0.00928	0.0432	CrCbGaD
Doxylamine—CHRM1—Circadian rythm related genes—DRD3—Gilles de la Tourette syndrome	0.00873	0.0111	CbGpPWpGaD
Doxylamine—CHRM1—Circadian rythm related genes—DRD4—Gilles de la Tourette syndrome	0.00848	0.0108	CbGpPWpGaD
Doxylamine—Promazine—HTR2A—Gilles de la Tourette syndrome	0.00825	0.0384	CrCbGaD
Doxylamine—CHRM1—Circadian rythm related genes—DRD2—Gilles de la Tourette syndrome	0.0079	0.0101	CbGpPWpGaD
Doxylamine—Imipramine—HTR2A—Gilles de la Tourette syndrome	0.00722	0.0336	CrCbGaD
Doxylamine—Amitriptyline—HTR2A—Gilles de la Tourette syndrome	0.00718	0.0334	CrCbGaD
Doxylamine—HRH1—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00717	0.00914	CbGpPWpGaD
Doxylamine—CHRM1—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00715	0.00911	CbGpPWpGaD
Doxylamine—HRH1—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00696	0.00887	CbGpPWpGaD
Doxylamine—CHRM1—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00694	0.00884	CbGpPWpGaD
Doxylamine—HRH1—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00649	0.00826	CbGpPWpGaD
Doxylamine—CHRM1—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00647	0.00824	CbGpPWpGaD
Doxylamine—HRH1—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00615	0.00783	CbGpPWpGaD
Doxylamine—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00613	0.0078	CbGpPWpGaD
Doxylamine—HRH1—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00597	0.0076	CbGpPWpGaD
Doxylamine—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00595	0.00758	CbGpPWpGaD
Doxylamine—HRH1—G alpha (q) signalling events—HTR2A—Gilles de la Tourette syndrome	0.00588	0.00749	CbGpPWpGaD
Doxylamine—CHRM1—G alpha (q) signalling events—HTR2A—Gilles de la Tourette syndrome	0.00586	0.00746	CbGpPWpGaD
Doxylamine—HRH1—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00556	0.00708	CbGpPWpGaD
Doxylamine—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00554	0.00706	CbGpPWpGaD
Doxylamine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.00526	0.0067	CbGpPWpGaD
Doxylamine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.00524	0.00667	CbGpPWpGaD
Doxylamine—HRH1—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00468	0.00596	CbGpPWpGaD
Doxylamine—CHRM1—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00466	0.00594	CbGpPWpGaD
Doxylamine—HRH1—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00454	0.00579	CbGpPWpGaD
Doxylamine—HRH1—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00454	0.00579	CbGpPWpGaD
Doxylamine—CHRM1—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00453	0.00577	CbGpPWpGaD
Doxylamine—CHRM1—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00453	0.00577	CbGpPWpGaD
Doxylamine—HRH1—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00423	0.00539	CbGpPWpGaD
Doxylamine—CHRM1—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00422	0.00537	CbGpPWpGaD
Doxylamine—HRH1—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00389	0.00496	CbGpPWpGaD
Doxylamine—CHRM1—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00388	0.00494	CbGpPWpGaD
Doxylamine—HRH1—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.00296	0.00378	CbGpPWpGaD
Doxylamine—CHRM1—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.00295	0.00376	CbGpPWpGaD
Doxylamine—HRH1—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.00264	0.00337	CbGpPWpGaD
Doxylamine—CHRM1—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.00264	0.00336	CbGpPWpGaD
Doxylamine—HRH1—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.00257	0.00327	CbGpPWpGaD
Doxylamine—CHRM1—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.00256	0.00326	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.0024	0.00306	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.00239	0.00305	CbGpPWpGaD
Doxylamine—HRH1—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.00239	0.00305	CbGpPWpGaD
Doxylamine—CHRM1—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.00238	0.00304	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.00233	0.00297	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.00232	0.00296	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.00217	0.00277	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.00216	0.00276	CbGpPWpGaD
Doxylamine—HRH1—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.00168	0.00213	CbGpPWpGaD
Doxylamine—CHRM1—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.00167	0.00213	CbGpPWpGaD
Doxylamine—HRH1—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.00152	0.00194	CbGpPWpGaD
Doxylamine—CHRM1—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.00152	0.00193	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.00142	0.00181	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.00141	0.0018	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.00138	0.00175	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.00137	0.00175	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.00128	0.00163	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.00128	0.00163	CbGpPWpGaD
Doxylamine—HRH1—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000899	0.00114	CbGpPWpGaD
Doxylamine—CHRM1—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000896	0.00114	CbGpPWpGaD
